Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;41(1):25-38.
doi: 10.1016/j.ccm.2019.10.003.

The Biology of Lung Cancer: Development of More Effective Methods for Prevention, Diagnosis, and Treatment

Ramin Salehi-Rad  1 , Rui Li  2 , Manash K Paul  2 , Steven M Dubinett  3 , Bin Liu  4
Affiliations
Review

The Biology of Lung Cancer: Development of More Effective Methods for Prevention, Diagnosis, and Treatment

Ramin Salehi-Rad et al. Clin Chest Med. 2020 Mar.

Abstract

Lung cancer is a heterogeneous disease with abundant genomic alterations. Chronic dysregulated airway inflammation facilitates lung tumorigenesis. In contrast, antitumor host immune responses apply continuous selective pressure on the tumor cells during the evolutionary course of the disease. Unprecedented advances in integrative genomic, epigenomic, and cellular profiling of lung cancer and the tumor microenvironment are enhancing the understanding of pulmonary tumorigenesis. This understanding in turn has led to advancements in lung cancer prevention and early detection strategies, and the development of effective targeted therapies and immunotherapies with survival benefit in selected patients.

Keywords: Biology of lung cancer; Genomic alterations; Immunotherapy; Lung cancer early detection; Lung cancer prevention; NSCLC and SCLC; Targeted therapy; Tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Disclosure S.M. Dubinett reports receiving a commercial research grant from Johnson & Johnson and is a consultant/advisory board member for LungLifeAI, Early Dx, Inc, the Johnson & Johnson Lung Cancer Initiative, and T-Cure Biosciences, Inc.